NCT04825262View on ClinicalTrials.gov

Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in Singapore

NACompletedINTERVENTIONAL
Enrollment

74

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

January 16, 2024

Study Completion Date

April 9, 2024

Conditions
Kidney Transplant RejectionKidney Transplant; Complications
Interventions
DRUG

Tacrolimus

Starting dose based on CYP3A5 genotype

Trial Locations (1)

767972

Singapore General Hospital, Singapore

All Listed Sponsors
lead

Singapore General Hospital

OTHER

NCT04825262 - Efficacy of Achieving Early Target Trough Levels of Tacrolimus Using CYP3A5 Guided Dosing Versus Weight-based Dosing in a Multi-ethnic Population of Kidney Transplant Recipients in Singapore | Biotech Hunter | Biotech Hunter